May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval
FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support, expanding the drug's initial adult indication. Takeda's Shire plc unit gained the analog of GLP-2 through its 2015 acquisition of NPS Pharmaceuticals Inc. in a $5.2 billion deal.

FDA approves first anticoagulant for pediatric patients
FDA also approved Fragmin dalteparin from Pfizer Inc. (NYSE:PFE) to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older, marking the first approved therapy for the indication. The agency approved the low molecular weight heparin for use in adults in 1994...